AMPK activation in the liver by 2-ME may explain the anti-steatosis and anti-insulin resistance effects of 2-ME, but it was not clear how 2-ME enhanced the secretion of insulin in mice under certain conditions. The gene discussed is PRKAA1; the disease is steatosis.